Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.53 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.53 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.53 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.53 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.42 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 6/20 | 0.40 |
| ▸ | CDC25A | P30304 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906068 | 0.98 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7906067 | 0.98 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6886076 | 0.97 | SSTR1 (0.53) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6887119 | 0.92 | SSTR1 (0.51) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6887112 | 0.92 | SSTR1 (0.51) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13381054 | 0.91 | SSTR5 (0.45) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13381041 | 0.90 | SSTR5 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3156185 | 0.90 | SSTR5 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7902126 | 0.90 | SSTR5 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6886072 | 0.88 | SSTR5 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
| US-6197963-B1 | TETRAHYDROPYRAN DERIVATIVES; PROTEIN G, SOMATOSTATIN, AND NATURAL KILLER CELL RECEPTOR ANTAGONISTS OR MIMETICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-03-06 | — | — | US | disclosed |
| US-5811512-A | BINDING TO G-PROTEIN-LINKED RECEPTORS, SUBSTANCE P RECEPTOR; HORMONE INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | SSTR1 1801/4885SSTR2 1551/4885SSTR4 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.